| HOME >> BIOLOGY >> TECHNOLOGY |
Selected Consolidated Operational Results (Unaudited)
Three Months Ended Nine Months Ended
September 30,
September 30,
2008 2007 2008 2007
Statements of Operations
Data:
Total Revenues $585,421 $364,330 $1,858,264 $903,133
Cost of goods sold (514,243) (318,934) (1,199,193) (823,676)
Gross profit 71,178 45,396 659,071 79,457
Research and
development 2,947,997 3,243,008 10,289,883 9,901,087
Selling, general and
administrative 2,886,089 2,838,949 8,968,214 8,356,498
Amortization -
Intangibles 197,414 178,156 592,242 592,242
Loss from
operations (5,960,322) (6,214,717) (19,191,268) (18,770,370)
Interest, Net (191,193) 146,748 (328,837) 461,371
Net loss (6,151,515) (6,067,969) (19,520,105) (18,308,999)
Net loss per common
share - basic and
diluted
(0.13) (0.15) (0.44) (0.47)
Weighted average
shares
outstanding-
basic and
diluted 46,603,700 40,928,219 44,322,663 38,759,118
Selected Consolidated
Balance Sheet Data: September 30, December 31,
2008 2007 (audited)
Cash and cash
equivalents $126,575 $7,722,816
Accounts receivable,
net 119,849 565,613
Inventory 1,818,021 1,037,164
Prepaid expenses and
other current assets 414,933 522,067
Property and equipment,
'/>"/>
| SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved |